Synaptogenix, Inc. Share Price Other OTC
Equities
SNPX
US87167T1025
Biotechnology & Medical Research
Sales 2022 | - | Sales 2023 | - | Capitalization | 5.54M 462M |
---|---|---|---|---|---|
Net income 2022 | -5M -416M | Net income 2023 | -6M -500M | EV / Sales 2022 | - |
Net cash position 2022 | 37.48M 3.12B | Net cash position 2023 | 30.1M 2.51B | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.42
x | P/E ratio 2023 |
-0.23
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 97.86% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01/18/01 |
Daniel Alkon
PSD | President | 81 | 07/20/07 |
Robert Weinstein
DFI | Director of Finance/CFO | 64 | 01/13/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Tuchman
CEO | Chief Executive Officer | 77 | 01/18/01 |
Bruce Bernstein
BRD | Director/Board Member | 60 | 14/16/14 |
Joshua Silverman
CHM | Chairman | 53 | 04/16/04 |
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |